Aptahem is active within biotechnology. The company conducts research and development of aptamer-based pharmaceuticals for the treatment of acute conditions caused by sepsis, blockage of blood vessels, stroke, and heart failure. Through early treatment, the pharmaceutical is intended to prevent damage to organs and tissue. A large part of the research is carried out in collaboration with partners within the industry. The company was founded in 2014 and is based in Malmö.

Quotes for Aptahem AB

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Mikael Lindstam

Chairperson of the Board

  • Bert Junno

Board

  • Johan Lindh
  • Mikael Lindstam
  • Theresa Comiskey Olsen
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    Aptahem - Småbolagsdagen Stockholm 12 juni 2023

    Intervju med Aptahems VD Mikael Lindstam

    Aptahem l Analyst Group intervjuar VD Mikael Lindstam om Q3 2022

    210827 APTAHEM INTERVJU

    Largest Owners

    Name Capital % Votes % Date
    Investment Aktiebolaget Balticum 8,10 8,10 2024-12-23
    Avanza Pension 7,34 7,34 2024-12-23
    Tuvedalen Ltd 5,18 5,18 2024-12-23
    Ivar Nordqvist 3,61 3,61 2024-12-23
    Fenja Capital Partners A/S 2,82 2,82 2024-12-23
    Nordnet Pensionsförsäkring 2,05 2,05 2024-12-23
    Magnus Renck 1,90 1,90 2024-12-23
    Marcus Milerud 1,81 1,81 2024-12-23
    Klas Göran Strömberg 1,27 1,27 2024-12-23
    Peter Cederström 1,16 1,16 2024-12-23
    ** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

    Insider trading

    *Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

    Key Numbers

    *Compiled data from Millistream

    Upcoming reports

    • 2025-04-08 Årsstämma 2024

    • 2025-05-28 Delårsrapport 2025-Q1

    Annual reports, prospectus etc.